RCUS

In May 2026, Arcus Biosciences reported Q1 2026 financial results with $17 million revenue and a $128 million net loss, reiterating a cash runway into at least H2 2028. In August 2026, Q2 2026 financial results showed $41 million revenue and a $91 million net loss, beating estimates, with management indicating a shift in R&D spending towards casdatifan. SEC filings in August 2026 confirmed Gilead's 24.7% ownership and noted officer share transactions. In September 2026, the company announced an investor event for October 20, 2026, to present new ARC-20 study data for casdatifan, highlighted as a key catalyst. Employment inducement grants were announced multiple times in September and October 2026. As of October 9, 2026, the stock was $24.41, up 61.0% over 12 months, but down 15.08% over 30 days and 16.81% over 90 days, trading below its 50-day moving average.